Description
Bio-Techne’s Hidden Growth Engine: COMET Surges As Core Markets Stay Soft!
Bio-Techne Corporation reported third quarter fiscal 2026 results reflecting a mixed performance amid varied end-market dynamics. Total revenue was $311.4 million, down 2% organically and reported, with foreign exchange providing a modest 2% tailwind and a 2% headwind from the prior Exosome Diagnostics divestiture. Adjusted earnings per share were $0.53, slightly below the prior year by $0.03, while GAAP EPS improved to $0.32 from $0.14. The company’s adjusted operating margin increased sequentially by 310 basis points to 34.2%, though it declined 70 basis points year-over-year due to unfavorable product mix and volume deleverage. The company highlighted sustained strength in its large pharmaceutical customer base, which delivered low double-digit growth for six consecutive quarters, alongside a stabilization and modest growth in the U.S. academic market.
